Milestone Pharmaceuticals (MIST) Free Cash Flow (2018 - 2026)
Milestone Pharmaceuticals' (MIST) quarterly Free Cash Flow came in at -$16.1 million in Q1 2026, down 15.33% YoY from -$19.0 million in Q1 2025, and down 23.28% on a QoQ basis from -$13.1 million in Q4 2025.
Milestone Pharmaceuticals (MIST) Free Cash Flow (2018 - 2026) Analysis & Trends
Milestone Pharmaceuticals (MIST) has 9 years of Free Cash Flow data on file, last reported at -$16.1 million in Q1 2026.
- Quarterly Free Cash Flow fell 15.33% year-over-year to -$16.1 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$51.5 million (down 51.88% YoY) and the FY2025 annual result came in at -$49.3 million, down 70.85% from the prior year.
- Free Cash Flow declined to -$16.1 million in Q1 2026, from -$13.1 million in the prior quarter.
- In the past five years, Free Cash Flow ranged from a high of -$6.1 million in Q2 2024 to a low of -$16.1 million in Q1 2026.
- A 5-year average of -$11.4 million and a median of -$12.2 million in 2023 frame the typical range for Free Cash Flow.
- Annual changes were most pronounced in 2022 — Free Cash Flow plunged 1487.68% — and 2024, when it surged 42.87%.
- Tracing MIST's Free Cash Flow over 5 years: stood at -$13.0 million in 2022, then advanced by 24.24% to -$9.8 million in 2023, then jumped by 30.14% to -$6.9 million in 2024, then plunged by 90.21% to -$13.1 million in 2025, then fell by 23.28% to -$16.1 million in 2026.
- The last three Free Cash Flow figures came in at -$16.1 million (Q1 2026), -$13.1 million (Q4 2025), and -$9.8 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Free Cash Flow (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 1.01 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 572.80 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -563.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 437.80 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 292.04 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 433.84 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -95.09 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 477.44 Mn |
| 10 | Milestone Pharmaceuticals | 43.40 Mn | -128.10 Mn | - | -22.74 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -22.74 Mn |
| Jun 30, 2026 | -22.74 Mn |
| Mar 31, 2026 | -16.10 Mn |
| Mar 31, 2026 | -16.10 Mn |
| Dec 31, 2025 | -13.06 Mn |
| Dec 31, 2025 | -13.06 Mn |
| Sep 30, 2025 | -9.75 Mn |
| Sep 30, 2025 | -9.75 Mn |
| Jun 30, 2025 | -12.58 Mn |
| Jun 30, 2025 | -12.58 Mn |
| Mar 31, 2025 | -13.96 Mn |
| Mar 31, 2025 | -13.96 Mn |
| Dec 31, 2024 | -6.87 Mn |
| Dec 31, 2024 | -6.87 Mn |
| Sep 30, 2024 | -7.02 Mn |
| Sep 30, 2024 | -7.02 Mn |
| Jun 30, 2024 | -6.05 Mn |
| Jun 30, 2024 | -6.05 Mn |
| Mar 31, 2024 | -8.93 Mn |
| Mar 31, 2024 | -8.93 Mn |